Gatifloxacin

Generic Name: Gatifloxacin

Brand Names: Zymar, Zymaxid

Drug Type: Small Molecule

Chemical Formula: C_₁₉H_₂₂FN_₃O_₄

CAS Number: 112811-59-3

Unique Ingredient Identifier: 81485Y3A9A

Background: Gatifloxacin is an antibiotic agent and a member of the fourth-generation fluoroquinolone family. It works by inhibiting the bacterial enzymes DNA gyrase and topoisomerase IV. It was first introduced by Bristol-Myers Squibb in 1999 under the brand name Tequin® for the treatment of respiratory tract infections. Gatifloxacin is available as tablets and in vari...

Indication: For the treatment of bronchitis, sinusitis, community-acquired pneumonia, and skin infections (abscesses, wounds) caused by S. pneumoniae, H. influenzae, S. aureus, M. pneumoniae, C. pneumoniae, L. pneumophila, S. pyogenes

Associated Conditions: Bacterial Conjunctivitis, Ocular Infections, Irritations and Inflammations

Associated Therapies: -

Clinical Trials

Efficacy of the Ophthalmic Pazufloxacin 0.6% for Bacterial Conjunctivitis, Compared to Gatifloxacin 0.3%.

Phase 3

Terminated

Conditions: Conjunctivitis, Bacterial

Interventions: Drug: Pazufloxacin
Drug: Zymar

First Posted Date: 2018-10-04

Last Posted Date: 2021-08-24

Lead Sponsor: Laboratorios Sophia S.A de C.V.

Target Recruit Count: 46

Registration Number: NCT03696342

Locations: 🇲🇽
Samuel altamirano Vallejo, Guadalajara, Jalisco, Mexico
🇲🇽
Juan Carlos Serna Ojeda (INBIOMEDyC), Aguascalientes, Mexico
🇲🇽
Instituto Nacional de Pediatria, Mexico City, Mexico

and more 3 locations

Gatifloxacin Versus Ceftriaxone in the Treatment of Enteric Fever

Phase 4

Completed

Conditions: Typhoid Fever
Enteric Fever

Interventions: Drug: Gatifloxacin
Drug: Ceftriaxone

First Posted Date: 2011-08-23

Last Posted Date: 2016-10-04

Lead Sponsor: Oxford University Clinical Research Unit, Vietnam

Target Recruit Count: 300

Registration Number: NCT01421693

Locations: 🇳🇵
Patan Hospital, Kathmandu, Nepal
🇳🇵
Civil Hospital, Kathmandu, Nepal

Besifloxacin Ophthalmic Suspension Verses Gatifloxacin Ophthalmic Solution in Neonates With Bacterial Conjunctivitis

Phase 3

Terminated

Conditions: Bacterial Conjunctivitis

Interventions: Drug: Besivance
Drug: Gatifloxacin

First Posted Date: 2011-04-06

Last Posted Date: 2014-09-03

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 33

Registration Number: NCT01330355

Locations: 🇺🇸
Bausch & Lomb Incorporated, Bridgewater, New Jersey, United States

Concentration of Besifloxacin, Gatifloxacin, and Moxifloxacin in Human Conjunctiva After Topical Instillation

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Moxifloxacin
Drug: Besifloxacin
Drug: Gatifloxacin

First Posted Date: 2009-05-21

Last Posted Date: 2011-12-09

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 119

Registration Number: NCT00905762

Locations: 🇺🇸
Bausch & Lomb Incorporated, Rochester, New York, United States

Assessment of the Concentrations of Besifloxacin, Moxifloxacin, or Gatifloxacin in the Aqueous Humor of Subjects

Phase 1

Completed

Conditions: Cataract Extraction

Interventions: Drug: Besifloxacin hydrochloride
Drug: moxifloxacin hydrochloride
Drug: gatifloxacin

First Posted Date: 2009-01-16

Last Posted Date: 2011-12-13

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 105

Registration Number: NCT00824070

Locations: 🇺🇸
Ophthalmic Consultants of Long Island, Rockville Center, New York, United States

A Study to Evaluate the Safety and Efficacy of Gatifloxacin for the Treatment of Bacterial Conjunctivitis

Phase 4

Completed

Conditions: Bacterial Conjunctivitis

Interventions: Drug: gatifloxacin
Drug: moxifloxacin 0.5% eye drops

First Posted Date: 2007-04-23

Last Posted Date: 2011-09-21

Lead Sponsor: Allergan

Target Recruit Count: 171

Registration Number: NCT00464438

Comparison of the Effect of 4th Generation Fluoroquinolones, Gatifloxacin and Moxifloxacin, on Epithelial Healing Following Photorefractive Keratectomy (PRK), A Substudy of: Initial Evaluation of Excimer Laser Keratorefractive Surgery in U.S. Army Personnel (WU # 2335-99)

Not Applicable

Completed

Conditions: Epithelium, Corneal

Interventions: Drug: Gatifloxacin
Drug: Moxifloxacin

First Posted Date: 2006-12-20

Last Posted Date: 2013-07-17

Lead Sponsor: Walter Reed Army Medical Center

Target Recruit Count: 40

Registration Number: NCT00414011

Locations: 🇺🇸
Walter Reed Army Medical Center, Washington, District of Columbia, United States

Topical Antibiotics and Intravitreous Injections

Phase 4

Completed

Conditions: Intravitreous
Injections

Interventions: Drug: gatifloxacin

First Posted Date: 2006-12-13

Last Posted Date: 2017-11-06

Lead Sponsor: Stanford University

Target Recruit Count: 129

Registration Number: NCT00410891

Locations: 🇺🇸
Stanford, Stanford, California, United States

Therapeutic Variables in Cataract Surgery

Phase 4

Completed

Conditions: Cataract Surgery

First Posted Date: 2006-12-04

Last Posted Date: 2007-08-21

Lead Sponsor: Innovative Medical

Registration Number: NCT00407017

Locations: 🇺🇸
The Center for Excellence in Eye Care, Miami, Florida, United States

Early Bactericidal Activity of Linezolid, Gatifloxacin, Levofloxacin, Isoniazid (INH) and Moxifloxacin in HIV Negative Adults With Initial Episodes of Sputum Smear-Positive Pulmonary Tuberculosis

Phase 1

Completed

Conditions: Tuberculosis

Interventions: Drug: Moxifloxacin
Drug: Gatifloxacin
Drug: Levofloxacin
Drug: Isoniazid
Drug: Linezolid

First Posted Date: 2006-11-06

Last Posted Date: 2018-11-08

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 70

Registration Number: NCT00396084

Locations: 🇺🇸
San Francisco General Hospital - Pulmonary and Critical Care Medicine, San Francisco, California, United States
🇧🇷
Universidade Federal do Espirito Santo - Duke Hubert-Yeargan Center, Vitória, Espírito Santo, Brazil

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy